Inogen Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Inogen wird ein jährliches Gewinn- und Umsatzwachstum von 17.7% bzw. 4.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 18.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -14.7% betragen.

Wichtige Informationen

17.7%

Wachstumsrate der Gewinne

18.9%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	4.2%
Zukünftige Eigenkapitalrendite	-14.7%
Analystenabdeckung	Low
Zuletzt aktualisiert	11 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

Mar 01

Recent updates

Inogen: Upside Seems Limited After Big Move Up

Sep 24

Inogen, Inc.'s (NASDAQ:INGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Jul 16

Inogen: Improving, But Still Struggling For Air

Jul 01

Inogen, Inc. (NASDAQ:INGN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

May 22

Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities

Apr 13

Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

Mar 01

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%

Feb 01

Inogen, Inc.'s (NASDAQ:INGN) Intrinsic Value Is Potentially 64% Above Its Share Price

Sep 20

Inogen: Structural, Supply Chain Headwinds Remain

Sep 13

Inogen Non-GAAP EPS of -$0.02 beats by $0.31, revenue of $103.38M beats by $2.74M

Aug 04

Inogen: Seasonal FCF, Tightening Margins, Supply Chain Headwinds

Jun 14

At US$35.28, Is It Time To Put Inogen, Inc. (NASDAQ:INGN) On Your Watch List?

Apr 03

Hammered By Supply Issues, Inogen Could Be A 2023 Comeback Story

Mar 31

Is There An Opportunity With Inogen, Inc.'s (NASDAQ:INGN) 28% Undervaluation?

Mar 09

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:INGN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	363	-33	10	39	3
12/31/2025	344	-38	N/A	28	4
12/31/2024	330	-41	0	17	4
9/30/2024	332	-53	-14	6	N/A
6/30/2024	327	-92	-20	1	N/A
3/31/2024	322	-97	-26	-2	N/A
12/31/2023	316	-102	-30	-3	N/A
9/30/2023	328	-133	-43	-16	N/A
6/30/2023	349	-96	-55	-27	N/A
3/31/2023	369	-90	-50	-26	N/A
12/31/2022	377	-84	-59	-38	N/A
9/30/2022	366	-50	-36	-16	N/A
6/30/2022	353	-28	-31	-9	N/A
3/31/2022	351	-20	-20	3	N/A
12/31/2021	358	-6	0	24	N/A
9/30/2021	356	11	9	33	N/A
6/30/2021	337	-2	20	43	N/A
3/31/2021	307	-5	19	39	N/A
12/31/2020	308	-6	19	37	N/A
9/30/2020	313	-2	16	30	N/A
6/30/2020	331	6	29	38	N/A
3/31/2020	360	14	36	43	N/A
12/31/2019	362	21	34	41	N/A
9/30/2019	370	32	37	44	N/A
6/30/2019	373	42	34	43	N/A
3/31/2019	369	46	35	46	N/A
12/31/2018	358	52	47	60	N/A
9/30/2018	335	41	44	61	N/A
6/30/2018	309	32	N/A	64	N/A
3/31/2018	276	26	N/A	60	N/A
12/31/2017	249	21	N/A	60	N/A
9/30/2017	237	27	N/A	53	N/A
6/30/2017	222	25	N/A	44	N/A
3/31/2017	212	24	N/A	39	N/A
12/31/2016	203	21	N/A	31	N/A
9/30/2016	192	19	N/A	38	N/A
6/30/2016	179	17	N/A	41	N/A
3/31/2016	168	13	N/A	37	N/A
12/31/2015	159	12	N/A	38	N/A
9/30/2015	148	9	N/A	30	N/A
6/30/2015	136	9	N/A	21	N/A
3/31/2015	123	7	N/A	23	N/A
12/31/2014	113	5	N/A	16	N/A
9/30/2014	103	6	N/A	13	N/A
6/30/2014	94	3	N/A	15	N/A
3/31/2014	83	1	N/A	9	N/A
12/31/2013	75	0	N/A	13	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: INGN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: INGN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: INGN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: INGNDie Einnahmen des Unternehmens (4.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: INGNDie Einnahmen des Unternehmens (4.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: INGN wird voraussichtlich in 3 Jahren unrentabel sein.

Inogen Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Inogen, Inc. Provides Revenue Guidance for the Full Year 2024

Consensus estimates of losses per share improve by 13%

Inogen, Inc. Provides Revenue Guidance for the Full Year 2024

Consensus EPS estimates upgraded to US$2.22 loss

Inogen, Inc. Provides Revenue Guidance for the Second Quarter of 2024

Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

Recent updates

New minor risk - Shareholder dilution

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Inogen, Inc. Provides Revenue Guidance for the Full Year 2024

Inogen, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Inogen Launches Rove 4 Portable Oxygen Concentrator, Delivering the Highest Oxygen Output in the Lightest Weight 4-Setting Poc

Inogen: Upside Seems Limited After Big Move Up

Consensus estimates of losses per share improve by 13%

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Inogen, Inc. Provides Revenue Guidance for the Full Year 2024

Inogen, Inc.'s (NASDAQ:INGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Inogen, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Inogen, Inc. Appoints Kevin P. Smith as General Counsel and Executive Vice President, Business Development, Effective July 22, 2024

Inogen: Improving, But Still Struggling For Air

Inogen, Inc. Announces Publication of Study Demonstrating the Association of Portable Oxygen Therapy with Decreased Survival and Increased Cost-Effectiveness Ratio

Inogen, Inc. (NASDAQ:INGN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Executive VP recently sold US$86k worth of stock

Consensus EPS estimates upgraded to US$2.22 loss

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Inogen, Inc. Provides Revenue Guidance for the Second Quarter of 2024

Insider exercised options and sold US$118k worth of stock

New minor risk - Shareholder dilution

Inogen, Inc., Annual General Meeting, Jun 05, 2024

Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities

Inogen, Inc. to Report Q1, 2024 Results on May 07, 2024

Insider exercised options and sold US$54k worth of stock

Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

Inogen, Inc. Provides Earnings Guidance for the First Quarter 2024

Full year 2023 earnings: EPS misses analyst expectations

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%

Inogen, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Inogen, Inc. Announces CFO Changes, Effective March 4, 2024

Inogen, Inc. Appoints Grgoire Ramade to Serve as Chief Commercial Officer

Inogen, Inc. Announces Separation Agreement with Nabil Shabshab

Inogen, Inc. Announces Separation Agreement with Nabil Shabshab

Inogen Announces CEO Changes

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Market cap size

Inogen, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Inogen (NASDAQ:INGN) In A Good Position To Deliver On Growth Plans?

Inogen, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 14%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Inogen, Inc. Announces the Introduction of the Rove 6(Tm) Portable Oxygen Concentrators in the United States

Inogen, Inc. Announces Board Changes

Inogen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Inogen (NASDAQ:INGN) Is In A Strong Position To Grow Its Business

Inogen, Inc. Reiterates Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Inogen, Inc. (NASDAQ:INGN) Worth US$13.3 Based On Its Intrinsic Value?

CEO, President & Director exercised options and sold US$130k worth of stock

Consensus EPS estimates fall by 53%

Full year 2022 earnings: EPS misses analyst expectations

Inogen, Inc. Announces Bart Sanford to Step Down as Executive Vice President, Operations Effective on or Before March 1, 2023

Inogen, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Executive VP & CTO exercised options and sold US$53k worth of stock

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Inogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Companies Like Inogen (NASDAQ:INGN) Can Afford To Invest In Growth

Inogen, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Inogen, Inc.'s (NASDAQ:INGN) Intrinsic Value Is Potentially 64% Above Its Share Price

Inogen: Structural, Supply Chain Headwinds Remain

CEO, President & Director exercised options and sold US$53k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

Inogen Non-GAAP EPS of -$0.02 beats by $0.31, revenue of $103.38M beats by $2.74M

Inogen, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Inogen, Inc.(NasdaqGS:INGN) dropped from Russell 2000 Growth-Defensive Index